from Yahoo Finance https://ift.tt/30coifg

Investigators could not find any online reviews, any documented employees or any established bank account for the defendant's purported BBQ company.

from Yahoo Finance https://ift.tt/3j4P95N

A nearly one-acre estate set on one of the most prime avenues in Atherton, arguably the Silicon Valley's most desirable residential neighborhood, recently popped up for sale with a $13.25 million pricetag. Tucked away behind walls and gates, the fully landscaped Tuscan-style spread is a bonafide compound with a three-level main house, detached guesthouse, and […]

from Yahoo Finance https://ift.tt/3j6NH2S

Imv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.What Happened? The Dartmouth, Nova Scotia-based company said it's rapidly progressing in developing DPX-COVID-19, its vaccine candidate against SARS-CoV2.The company said it's working closely with regulators and collaborators to kickstart the Phase 1 study as quickly as possible. Health Canada has already approved the clinical trial design of the study, it added."The rapid progress in target selection, the vaccine formulation, manufacturing and preclinical results so far not only demonstrate the potential of our delivery platform, but also build on our previously reported clinical data from a similarly designed vaccine against RSV, the respiratory syncytial virus," said Frederic Ors, CEO of IMV.What's Next? IMV plans to conduct the early-stage study as a randomized controlled study, assessing the safety and immunogenicity of two doses of DPX-COVID-19, in 84 healthy adults across two age cohorts – adults, ages 18-55 years and ages 56 and above.IMV said multiple batches of DPX-COVID-19 have been successfully produced.The Phase 1 study is planned for the fall. Contingent on positive results from the study, the company plans to initiate Phase 2 trials in the second half of the year.IMV shares were rallying 69% to $5.07 at the time of publication.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Week Ahead In Biotech: ASCO Presentations In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/2WhwU34

On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

from Yahoo Finance https://ift.tt/3gZzjY2

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

from Yahoo Finance https://ift.tt/30ejVjM

Moderna Inc said on Tuesday it plans to start a late stage clinical trial for its COVID-19 vaccine candidate on or around July 27, according to its listing for the phase 3 study at clinicaltrials.gov. Moderna said it will conduct the trial at 87 study locations, all in the United States. The experimental vaccine will be tested in 30 states and Washington, D.C. Around half of the study locations are in hard-hit states like Texas, California, Florida, Georgia, Arizona and North and South Carolina.

from Yahoo Finance https://ift.tt/2DEgXgV

On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

from Yahoo Finance https://ift.tt/30595N4

On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]

from Yahoo Finance https://ift.tt/2Om4osT

Headline grabbing biotechs are far from a rare sight in 2020. Nevertheless, when a little-known micro-cap pops by 730% in a single trading session, avid market followers are likely to take notice.And so to Equillium (EQ), the aforementioned little known biotech, whose shares blasted off on Monday.The rally began following the announcement that the Drugs Controller General of India – India’s equivalent of the FDA – granted Equillium's partner Biocon emergency approval for itolizumab, a treatment of cytokine release syndrome (CRS) in COVID-19 patients with acute respiratory distress syndrome (ARDS). The approval came following a 30-patient proof-of-concept trial in which the drug reduced mortality in hospitalized COVID-19 patients (all patients given the drug survived).The drug is currently being developed as a treatment for various autoimmune and inflammatory diseases. However, Equillium now plans to file an investigational new drug (IND) application so it can proceed with a clinical trial of itolizumab in COVID-19 patients in the US.H.C. Wainwright analyst Ram Selvaraju believes progress could be fast once the wheels are set in motion.“In our view,” said the 5-star analyst, “itolizumab could be developed rapidly using a similar trial design in a larger patient group—perhaps no more than 200-400 subjects—with a randomized, double-blinded, controlled approach. Such a trial program in the U.S. could be accomplished involving only 10-12 centers and might cost under $10M to execute. If started in the next several weeks, we believe such a trial could yield results in early 4Q20 and facilitate either accelerated approval or Emergency Use Authorization from the FDA before year-end.”Selvaraju estimates that the “penetration rate” in the U.S. for the treatment won’t exceed 3.5%, as the patients eligible to receive itolizumab – those with specific types of immunological and respiratory complications – make up less than 15% of all COVID-19-infected patients.The analyst reckons the treatment will sell for approximately $1,750 per course, and could notch “potential peak sales of over $500 million in the U.S. market by 2022,” after which sales are expected to decline as the pandemic gradually retreats.To this end, Selvaraju boosts his price target on EQ to $24 (from $14), which implies about 70% upside from current levels. (To watch Selvaraju’s track record, click here)Only one other analyst has posted an EQ review over the last 3 months, also recommending a Buy. (See Equillium stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/30cqCmn